- Home
- SST vs IFRX Comparison
SST vs IFRX Comparison
Compare SST & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | IFRX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 86.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SST | IFRX |
|---|---|---|
| Price | $4.36 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $10.00 | $8.50 |
| AVG Volume (30 Days) | 27.5K | ★ 6.5M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $0.71 |
| 52 Week High | $15.00 | $2.77 |
Technical Indicators
Market Signals| Indicator | SST | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 43.05 |
| Support Level | $3.54 | $0.92 |
| Resistance Level | $4.01 | $1.12 |
| Average True Range (ATR) | 0.43 | 0.10 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 60.82 | 39.73 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.